Idraparinux

Idraparinux

Clinical data
Routes of administration	subcutaneous
Pharmacokinetic data
Elimination half-life	80-130 hours
Identifiers
IUPAC name Nonasodium (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6- [(2R,3S,4S,5R,6R)-2-carboxylato- 4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5- disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl] oxyoxan-3-yl]oxy-4,5-disulfonatooxy- 2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy- 3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy- 6-(sulfonatooxymethyl)oxan-2-yl]oxyoxane- 2-carboxylate
CAS Number	149920-56-9
PubChem CID	3083444
Chemical and physical data
Formula	C38H55Na9O49S7
Molar mass	1727.17683 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)[O-])O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)[O-])O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Idraparinux sodium is an anticoagulant medication with a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer. It needs to be applied only once a week.

As of July 2007, it has completed the Phase III clinical trial AMADEUS.

Method of action

Idraparinux selectively blocks coagulation factor Xa.

See Heparin: Mechanism of anticoagulant action for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.